MANGOCEUTICALS, INC. — fact timeline

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(b)).

“February 4, 2026, Mangoceuticals, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company can regain compliance with the minimum bid price requirement at any time within the 180-calendar day period following receipt of the Nasdaq”

MANGOCEUTICALS, INC. entered into Master Services Agreement with Cube Operations LLC (effective 2025-12-17).

“On December 17, 2025, Mango DAT, LLC (“Mango DAT”), a wholly owned subsidiary of Mangoceuticals, Inc. (the “Company”) and Cube Operations LLC (“Cube”) entered into a Master Services Agreement (the “Agreement”).”

MANGOCEUTICALS, INC. entered into Purchase Agreement with an institutional investor valued at aggregate gross proceeds of approximately $2.5 million (effective 2025-12-18).

“On December 18, 2025, Mangoceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to such investor (a) in a registered direct offering, (A) 1,430,502 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $1.295 per share, and (B) 500,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of the Common Shares, at an offering price of $1.29499 per Pre-Funded Warrant (such registered direct offering, the “Offering”), and (b) in a concurrent private placement, common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 1,930,502 shares of Common Stock, at an exercise price of $1.4245 per warrant share for aggregate gross proceeds of approximately $2.5 million.”

MANGOCEUTICALS, INC. issued 500,000 pre-funded warrants of warrant to institutional investor for $1.29499 per Pre-Funded Warrant.

“registered direct offering, (A) 1,430,502 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $1.295 per share, and (B) 500,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of the Common Shares, at an offering price of $1.29499 per Pre-Funded Warrant (such registered”

MANGOCEUTICALS, INC. issued an aggregate of up to 1,930,502 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds of approximately $2.5 million.

“exercisable for an aggregate of up to 1,930,502 shares of Common Stock, at an exercise price of $1.4245 per warrant share for aggregate gross proceeds of approximately $2.5 million. The Pre-Funded Warrants are immediately exercisable and may be exercised at an exercise price of $0.00001 per warrant share at any time until all of the Pre-Funded Warrants are”

MANGOCEUTICALS, INC. issued 1,430,502 shares of common stock to institutional investor for $1.295 per share.

“registered direct offering, (A) 1,430,502 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $1.295 per share, and (B) 500,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of the Common Shares, at an offering price of $1.29499 per Pre-Funded Warrant (such registered”

MANGOCEUTICALS, INC. entered into Promissory Note with The Tiger Cub Trust valued at $75,000 (effective 2025-12-04).

“On December 4, 2025, Mangoceuticals, Inc. (the “ Company ”, “ we ” and “ us ”), borrowed $75,000 from The Tiger Cub Trust, which trust is controlled by the Company’s Chief Executive Officer and Chairman, Jacob D. Cohen (“ Tiger Cub ”), and entered into a Promissory Note with Tiger Cub to evidence such loan.”

MANGOCEUTICALS, INC. issued 23,466 shares of common stock of common stock to Platinum Point Capital, LLC for conversion of 32 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $35,200) pursuant to a conversion price of $1.50 per share.

“On October 16, 2025, Platinum Point Capital, LLC, a holder of the Company’s Series B Convertible Preferred Stock, converted 32 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $35,200) into 23,466 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $1.50 per share.”

MANGOCEUTICALS, INC. issued 366,667 shares of common stock of common stock to Indigo Capital LP for conversion of 500 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $500,000) pursuant to a conversion price of $1.50 per share.

“On September 15, 2025, Indigo Capital LP, a holder of the Company’s Series B Convertible Preferred Stock, converted 500 shares of Series B Convertible Preferred Stock (with an aggregate stated value of $500,000) into 366,667 shares of common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $1.50 per share.”

MANGOCEUTICALS, INC. completed an acquisition involving Smokeless Technology Corp. (closed 2025-04-24).

“The IP Purchase Agreement, and the purchase of the Purchased IP, closed on April 24, 2025, upon the parties entry into the IP Purchase Agreement”

MANGOCEUTICALS, INC. incurred loan of $500,000 with Indigo Capital LP at 18% per annum, compounded monthly maturing April 15, 2026.

“The Company's entry into the Promissory Note represents a direct financial obligation in the principal amount of $500,000, plus applicable interest, fees, and potential prepayment premiums and default payments, as described above.”

MANGOCEUTICALS, INC.: Filed an amendment to Certificate of Designations of Series B Preferred Stock to reduce conversion price from $2.25 to $1.50, reduce floor price from $2.25 to $1.50, remove dividend rights, and exclude subsidiary from Change of Control definition (effective 2025-03-17).

“On March 17, 2025, with the approval of the shareholders of the Company, as discussed in greater detail under Item 5.07 , the Company submitted to the Secretary of the State of Texas, an amendment to the Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc. (the “ Series B Designation ”), to: (a) reduce the conversion price set forth therein to a fixed price of $1.50 per share (subject to customary adjustments for stock splits) (compared to having a fixed conversion price of $2.25 prior to the amendment)(the “ Conversion Price ”); (b) reduce the floor price set forth therein from $2.25 to $1.50 per share (subject to customary adjustments for stock splits)(the “ Floor Price ”); (c) remove the dividend rights set forth therein (except for standard participatory rights for dividends declared on the Company’s common stock); and exclude the Company’s current wholly-owned subsidiary, Mango & Peaches Corp. (“ Mango & Peaches ”), fr”

Amanda Hammer changed role as Chief Operating Officer at MANGOCEUTICALS, INC..

“Pursuant to the Hammer Amendment, Ms. Hammer’s role with the Company was expanded to include serving as Chief Operating Officer of Mango & Peaches Corp.,”

Antonios Isaac was appointed as Director at MANGOCEUTICALS, INC..

“appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.”

Antonios Isaac was appointed as President at MANGOCEUTICALS, INC..

“appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.”

MANGOCEUTICALS, INC.: Subsidiary M&P filed a Certificate of Designations establishing Series A Super Majority Voting Preferred Stock (effective 2025-01-09).

“On January 9, 2025, Mango & Peaches Corp. (“ M&P ”), the current wholly-owned subsidiary of Mangoceuticals, Inc., a Texas corporation (the “ Company ”, “ we ” and “ us ”), filed a Certificate of Designations of Mango & Peaches Corp., establishing the designations, preferences, limitations, and relative rights of its Series A Super Majority Voting Preferred Stock (the “ Series A Preferred Stock ”), with the Secretary of State of Texas”

MANGOCEUTICALS, INC. completed an acquisition involving Greenfield Investments, Ltd for 515,000 shares of the Company’s restricted common stock (closed 2024-12-13).

“certain patents owned by Greenfield, related to nutraceutical compositions using fungal compounds derived from mushrooms (collectively, the “ Patents ”), in consideration for 515,000 shares of the Company’s restricted common stock (the “ IP Purchase Shares ”). The IP Purchase Agreement, and the purchase of the Patents, closed on December 13, 2024, upon the”

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“filed by the Company with the Commission on November 7, 2023, on November 3, 2023, the Company received a letter from Nasdaq notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “ Rule ”), which requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the Company reported stockholders’ equity of $1,354,821, which is”

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 30, 2023, the Company received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues”

MANGOCEUTICALS, INC.: Filed a Certificate of Designations establishing the 6% Series C Convertible Cumulative Preferred Stock, designating 6,250,000 shares with specific dividend, liquidation, conversion, voting, protective, and redemption terms (effective 2024-04-19).

“On April 19, 2024, the Company submitted for filing to the Secretary of State of Texas, a Certificate of Designations of Mangoceuticals, Inc. Establishing the Designations, Preferences, Limitations and Relative Rights of Its 6% Series C Convertible Cumulative Preferred Stock (the “ Series C Designation ”), which was filed with the Secretary of State of Texas on April 23, 2024, effective as of April 19, 2024.”

MANGOCEUTICALS, INC. completed an acquisition involving Intramont Technologies, Inc. for $20,000,000 (closed 2024-04-24).

“infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the “ Patents ”), in consideration for $20,000,000, which is payable to Intramont by (a) the issuance of 980,000 shares of the Company’s newly designated 6% Series C Convertible Preferred Stock (the “ Series C Preferred Stock”

MANGOCEUTICALS, INC. entered into Patent Purchase Agreement with Intramont Technologies, Inc. valued at $20,000,000 (effective 2024-04-24).

“Mangoceuticals, Inc., a Texas corporation (the “ Company ”, “ we ” and “ us ”), entered into a Patent Purchase Agreement (the “ IP Purchase Agreement ”), with Intramont Technologies, Inc. (“ Intramont ”).”

MANGOCEUTICALS, INC. entered into Securities Purchase Agreement with an institutional accredited investor valued at $1,650,000 (effective 2024-04-05).

“Effective on April 5, 2024 (the " Initial Closing Date "), Mangoceuticals, Inc., a Texas corporation (the " Company ", " we " and " us "), agreed to definitive terms on a Securities Purchase Agreement dated April 4, 2024 (the " SPA "), with an institutional accredited investor (the " Purchaser "), pursuant to which the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 1,500 shares of Series B Convertible Preferred Stock (" Series B Preferred Stock ") of the Company for $1,650,000, and warrants”

MANGOCEUTICALS, INC. entered into Underwriting Agreement with Boustead Securities, LLC, as representative of the underwriters valued at $1.2 million (effective 2023-12-15).

“On December 15, 2023, Mangoceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Boustead Securities, LLC, as representative (the “ Representative ”) of the underwriters named on Schedule 1 thereto (the “ Underwriters ”), relating to a public offering of the Company’s common stock (the “ Offering ”).”

MANGOCEUTICALS, INC. entered into Marius Agreement with Marius Pharmaceuticals, LLC valued at 100,000 shares of our restricted common stock (effective 2023-12-10).

“On December 10, 2023, we entered into a Marketing Agreement with Marius Pharmaceuticals, LLC (“ Marius ”) allowing us the use of the trademark “Kyzatrex®” oral testosterone undecanoate softgel capsules”

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Form 10-Q, the Company reported stockholders’ equity of $1,354,821, which is below the minimum stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). Additionally, as of the date of this Report, the Company”

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 30, 2023, Mangoceuticals, Inc. (the “Company”) received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if”

MANGOCEUTICALS, INC. amended First Addendum to Master Services Agreement with Epiq Scripts, LLC (effective 2023-09-15).

“and (2) a First Addendum to Master Services Agreement with Epiq Scripts (the " First Amendment "), which amended that certain Master Services Agreement dated September 1, 2022, by and between the Company and Epiq Scripts (the " MSA ")”

MANGOCEUTICALS, INC. entered into Consulting Agreement with Epiq Scripts, LLC (effective 2023-09-15).

“On September 15, 2023, Mangoceuticals, Inc. (the " Company ", " we " and " us ") entered into (1) a Consulting Agreement (the " Consulting Agreement ") with Epiq Scripts, LLC (" Epiq Scripts ")”

Jonathan Arango changed role as Chief Operating Officer at MANGOCEUTICALS, INC..

“As a result of such appointment Jonathan Arango, the President, Secretary and member of the Board of Directors of the Company, ceased serving as COO, but will continue serving in his other roles with the Company.”

Amanda Hammer was appointed as Chief Operating Officer at MANGOCEUTICALS, INC..

“Effective on May 1, 2023, the Board of Directors of Mangoceuticals, Inc. (the “ Company ”, “ we ” and “ us ”) appointed Mrs. Amanda Hammer, as the Chief Operating Officer (COO) of the Company.”